| Autor: |
null Abdullah Al Shafi Majumder, null Mohammad Ullah, null Md. Toufiqur Rahman, null AKM Monowarul Islam, null Md Alimur Reza, null Khondokar Asaduzzaman, null SM Quamrul Huq, null Abu Zahid Bosunia, null Durul Hoda, null Solaiman Mia, null Moniruzzaman, null Goutam Kumar Acherjya, null Abdur Rahim, null Anisul Awa l, null Ashraf Uddin Chowdhury, null Azizur Rahman Roman, null Dipankar Chandra Nag, null Durba Halder, null Gobinda Kanti Paul, null K. M. Kamal, null Md. Abul Khair, null Md. Ajmirul Hoque Sarkar, null Md. Fakhrul Islam Juwel, null Md. Khalequzzaman, null Md. Mahbubur Rahman, null Md. Mizanur Rahman, null Md. Mushfequr Rahman Khan, null Md. Nuruddin Tareq, null Md. Rayhan Masum Mandal, null Md. Saiful Islam, null Md. Sk. Mamun, null Md. Zillur Rahman, null Mezbah Uddin Ahmed, null Mir Md. Muntaquim Haider, null Moeen Uddin Ahmed, null Mohammad Nasir Uddin, null Molla Md Iftekhar Hossain, null Nishit Kumar Majumder, null Nur Alam, null Prashanto Kumar Swarnoker, null Rajesh Kumar Gosh, null Rajib Gosh, null Ranjit C. Khan, null Rashid Ahmed, null Sahela Nasrin, null Shahana Zaman, null Shahriar Kabir, null Sheikh Marufuzzaman, null Shishir Kumar Basak, null Sirajur Rahman Sarwar, null Solaiman Hossain, null Solaiman Tanvir, null Sufia Jannat, null Sujit Kumar Chanda, null Swadesh Kumar Chakrovortty, null Syed Nasir Uddin, null Zahiruddin Mahmud Ilias, null Miah Mohammad Jamsidul Hassan |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| DOI: |
10.5281/zenodo.7769254 |
| Popis: |
Background:Uncontrolled blood pressure (BP) is a major healthcare issue and responsible for high risk of cardiovascular disease (CVD) mortality and morbidity. Physicians of Bangladesh had been usingamlodipine and Olmesartan combination for a long period of time but have very limited evidence-based information regarding the efficacy and safety of this combination.The aim of this study was to evaluate the efficacy and safety of fixed dose combination of olmesartan/amlodipine in hypertensive patients. Methods:This open-label, non-randomized, non-comparative observational study was conducted in different centers of Bangladesh during the period from January 2020 to November 2020. In total 443 Bangladeshi adult patients with hypertension were selected as the study population. Proper written consent was taken from all the participants before collecting data. Inter-group differences in the baseline characteristics were compared using analysis of variance (ANOVA). Two-tailed p-values of less than 0.05 were considered to be statistically significant. Statistical analyses were conducted by using SPSS for Windows, version 25 (SPSS Inc., Chicago, IL, USA). Results:Among all the participants, more than 70% were above 46 years of age and 55% were male. More than 60% of them were either overweight or obese. Among them, dyslipidemia, diabetes, and Chronic renal failure (CRF) was found among 14.22%, 28.44%, and 4.29% participants respectively Mean systolic (SBP) and diastolic blood pressures (DBP) were reduced to 36.61 and 18.69 mm of Hg respectively after 12 weeks of therapy. Besides these, the targeted SBP was achieved among 92% and targeted DBP was achieved among 98.3% of participants after 12 weeks. Achievement of BP goal in respect to Body mass index (BMI) of the patient (P-value 0.019), family history of hypertension (P-value 0.028), and dose of the drug in initial visit (P-value 0.001) was found statistically significant. There was no discontinuation of study medication due to intolerance or adverse events. Conclusion:Olmesartan/Amlodipine is an effective combination for reducing the blood pressure along with achievement of BP goal. Future studies on Olmesartan/Amlodipine in Bangladesh could be conducted with a longer treatment duration to examine the maintenance of effect and long-term safety. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
